Rapid Pain and Skin Improvement of Chronic Hand Eczema with Delgocitinib Cream

Document Type

Article

Publication Date

5-11-2026

Publication Title

Skin

Abstract

Chronic hand eczema (CHE) is a common inflammatory dermatosis affecting up to 10% of the general population and is associated with pain, impaired hand function, and reduced quality of life. Despite its prevalence and morbidity, effective and well-tolerated treatment options remain limited. Delgocitinib 2% cream, a recently FDA-approved topical nonsteroidal pan–Janus kinase (JAK) inhibitor, has demonstrated efficacy across multiple CHE subtypes in clinical trials. We report a case of rapid and complete symptomatic remission in a patient with a six-month history CHE presenting with fingertip fissures, edema, erythema, moderate pain (5/10), and mild pruritus (1/10), and an Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE) score of 4. Following initiation of delgocitinib monotherapy, marked clinical improvement was observed within four days, with the IGA-CHE improving to 1 and both pain and itch reaching 0/10. Remission was sustained throughout the seven-day observation period while continuing the medication as prescribed. This case highlights the potential of topical pan-JAK inhibition to rapidly improve both objective disease features and patient-reported outcomes, particularly pain and pruritus, which substantially contribute to CHE-related quality-of-life impairment.

First Page

3163

Last Page

3169

Volume

10

Issue

3

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Link to Full Text

Share

COinS